A retrospective survey evaluating the prescribing tendencies of UK veterinary surgeons, relating to the use of anti-inflammatory drugs in canine angiostrongylosis

2021 ◽  
Vol 12 (4) ◽  
pp. 186-192
Author(s):  
Amy Loverance ◽  
Ian Wright ◽  
Mark Dunning ◽  
Hany Elsheikha
Keyword(s):  
Endemic Area ◽  
Retrospective Survey ◽  
Regional Comparison ◽  
Immune Mediated ◽  
Veterinary Surgeons ◽  
Referral Practices ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
South East England ◽  
Survey Responses

Background: In addition to anti-parasitic therapy, appropriate supportive care is vital for the successful treatment of canine angiostrongylosis. Aim: This study sought to determine the prevalence and reasons for the use of corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), by veterinarians, as a supportive treatment for canine angiostrongylosis. Specifically, the study investigated the use of anti-inflammatory drugs in the management of inflammation, anaphylaxis and immune-mediated thrombocytopenia, which can develop in some dogs infected by Angiostrongylus vasorum. Methods: These aims were achieved by surveying UK veterinarians from a non-endemic area, Yorkshire, and an endemic area, South East England, for canine angiostrongylosis. Responses were received from independent, corporate-owned and referral practices. Results: Overall, more veterinarians would administer corticosteroids (80%) compared with NSAIDs (40%). Most respondents surveyed stated administration would be case dependent, including the severity of perceived inflammation. Four of six veterinarians who would never administer NSAIDs cited coagulopathies as the reason for their decision-making. While the regional comparison here revealed no significant differences, wider sampling may produce identifiable trends. Conclusion: The survey responses revealed a lack of understanding of if, when, and why, anti-inflammatories should be administered. Imperatively, further research is needed to address this lacuna.

Practical use of non-steroidal anti-inflammatory drugs in farm practice

Livestock ◽  
2020 ◽  
Vol 25 (5) ◽  
pp. 202-209
Author(s):  
Jon Reader ◽  
Tom Angel ◽  
Imogen Rogers
Keyword(s):  
Pain Relief ◽  
Mode Of Action ◽  
Food Production ◽  
Evidence Base ◽  
Farm Animal ◽  
Farm Animals ◽  
Basic Mode ◽  
Veterinary Surgeons ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

The importance of pain relief in farm animals has never been further up the agenda for modern food production and farm animal practice. This has been driven by increased awareness amongst farmers, veterinary surgeons and consumers. This article looks at the practical use of non-steroidal anti-inflammatory drugs (NSAIDs) in farm animal practice for both adults and youngstock. The basic mode of action of NSAIDs is discussed and some of the evidence base that has been growing over the use of NSAIDs in cattle. It also highlights some of the present requirements of some of the retailers and auditing bodies.

scholarly journals AB0001 INTERFERON SIGNATURE IN CHILDREN WITH CHRONIC NON-BACTERIAL OSTEOMYELITIS AND IT’S DYNAMIC AFTER BISPHOSPHONATES TREATMENT

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1036.2-1036
Author(s):  
M. Kostik ◽  
R. Raupov ◽  
R. Mulkidzhan ◽  
A. Kosmin ◽  
E. Suspitsin
Keyword(s):  
Lupus Erythematosus ◽  
Treatment Options ◽  
Basic Research ◽  
Cytokine Release ◽  
Interferon Signature ◽  
Immune Mediated ◽  
Main Adverse Event ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Basic Research Grant

Background:Chronic non-bacterial osteomyelitis (CNO) is an immune-mediated chronic inflammatory bone disease which predominantly affects children and adolescents. The pathogenesis of CNO related to imbalance between pro-inflammatory and anti-inflammatory cytokines. Interferon-I mediated pathway is associated with pathogenesis of different pediatric rheumatic diseases, such as juvenile systemic lupus erythematosus (jSLE), juvenile dermatomyositis (JDM), systemic onset of juvenile idiopathic arthritis (soJIA), and, most of all, with macrophage activation syndrome. The data on interferon-I- regulated pathway in CNO is absent. NSAIDs, non-biologic and biologic anti-inflammatory drugs and bisphosphonates (BF) are treatment options for patients with CNO. The main adverse event of BF is a flu-like syndrome probably caused by the excessive cytokine release stimulated by BF.Objectives:The aim of our study was to evaluate activity of Interferon-I mediated pathway in CNO patients and it’s dynamics after BF treatment.Methods:This prospective study included children with CNO requiring BF treatment (n=9), patients with soJIA (n=8), JDM (n=11) and jSLE (n=40) and healthy controls (HC, n=21). The activity of Interferon-I mediated pathway was assessed using interferon I score (IFN1 score). The score represented the median expression of 5 IFN1-regulated genes (IFI44L, IFI44, IFIT3, LY6E, MX1) measured by quantitative real-time PCR. Patients with CNO were treated with standard 3-day regimen (1 mg/kg/day). We measured interferon score before pamidronate (Day 0, n=9) and after (Day 3, n=7).Results:Median interferon score was 1.09 (0.96; 1.67) in CNO patients, 1.95 (1.3; 5.75) in soJIA, 7.6 (1.78; 29.0) in JDM and 16.9 (2.55; 40.3) in jSLE and 0.95 (0.82; 1.17) in HC (p=0.00001). Where were no difference in the IFN1 score between CNO and HC (p=0.222). In 6/7 CNO patients interferon score increased after pamidronate (p=0.015). The median interferon score after pamidronate increased and became 3.06 (0.87; 4,9, p=0.043); this may possibly explain the development of BF-related flu-like symptoms (cytokine release syndrome).Conclusion:While interferon I-regulated pathway is not directly associated with CNO pathogenesis, BF likely activates interferon-I-regulated pathway and thus could be a possible cause of flu-like syndrome.This work supported by the Russian Foundation for Basic Research (grant № 18-515-57001).Disclosure of Interests:None declared

scholarly journals Nemszteroid gyulladáscsökkentő szerek a mozgásszervi fájdalom csillapításában

2019 ◽  
Vol 160 (22) ◽  
pp. 855-860
Author(s):  
Gábor Sütő
Keyword(s):  
Pain Control ◽  
Adverse Reactions ◽  
Cardiovascular Complications ◽  
Degenerative Disorders ◽  
Relieve Pain ◽  
Immune Mediated ◽  
Long Time ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Abstract: Pain control in musculoskeletal disorders is still a challenging task. The most effective treatment of pain in autoimmune and immune-mediated diseases is the treatment of the disease itself. Analgesics, non-steroidal anti-inflammatory drugs and opioids are used to relieve pain. Analgesia is the central intervention of degenerative disorders. The most effective analgesic compounds are the non-steroidal anti-inflammatory drugs (NSAIDs). Concerns are raised regarding the safety of NSAIDs. There is not any organ which is not involved in adverse reactions, but the damage of the gastrointestinal system has been considered the most serious one for a long time. In the 21st century, the recognition of cardiovascular complications led to the re-evaluation of the role of these drugs in analgesia. Orv Hetil. 2019; 160(22): 855–860.

Ankylosing Spondylitis: A Risk Factor for Parkinsonism—A Nationwide Population-Based Study

2021 ◽  
pp. 1-8
Author(s):  
Seo Yeon Yoon ◽  
Seok-Jae Heo ◽  
Yong Wook Kim ◽  
Seung Nam Yang ◽  
Hyun-Im Moon
Keyword(s):  
Ankylosing Spondylitis ◽  
Population Based ◽  
Atypical Parkinsonism ◽  
Protective Effects ◽  
Subdistribution Hazard ◽  
Neurodegenerative Process ◽  
Immune Mediated ◽  
Increased Risk ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Background: Ankylosing spondylitis (AS) is an immune-mediated, chronic inflammatory rheumatic disorder. The etiology of Parkinson’s disease (PD) is multifactorial; however, inflammation is receiving an increasing amount of attention as an underlying cause of the neurodegenerative process of PD. Objective: We performed a nationwide longitudinal, population-based matched cohort study to assess the association with the later development of parkinsonism in Korea. Methods: This study was conducted using records from the Health Insurance Review and Assessment Service database. The cumulative incidence rate of PD was estimated. Fine–Gray subdistribution hazard models were used to identify hazards associated with PD development based on the presence of AS. Exposure to anti-inflammatory drugs was measured and analyzed to determine the protective effect of these medications. Additionally, the hazard ratio (HR) for atypical parkinsonism was estimated. Results: The results of the Fine–Gray subdistribution hazard model revealed that the HR for PD development in the AS group was 1.82 (95%confidence interval [CI], 1.38–2.39, p <  0.001). A significant decrease in PD development was observed in patients with AS taking non-steroidal anti-inflammatory drugs (NSAIDs). The HR for atypical parkinsonism in the AS group was 3.86 (95%CI, 1.08–13.78, p <  0.05). Conclusion: We found that AS was associated with an increased risk of PD and atypical parkinsonism. NSAIDs used for AS control have some protective effects against PD. Further studies assessing whether biological treatment mitigates PD risk in patients with high activity are warranted.

scholarly journals Nemszteroid gyulladáscsökkentők okozta adverz reakciók differenciáldiagnosztikája. In vitro és in vivo módszerek

2018 ◽  
Vol 159 (38) ◽  
pp. 1556-1566
Author(s):  
József Mátyás Baló-Banga ◽  
Katalin Schweitzer
Keyword(s):  
Plasma Membranes ◽  
Mononuclear Cells ◽  
In Vitro Tests ◽  
Immune Mediated ◽  
Release Assay ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Cox 1

Abstract: Introduction: According to the present knowledge, the effect of non-steroidal anti-inflammatory drugs (NSAIDs) depends on the inhibitory ratio of cyclooxigenase (COX)-1 to COX-2 in the plasma membranes. In addition to cardiovascular and gastrointestinal side effects, there are adverse symptoms which can be divided into cross-intolerance (non-immune mediated) and single or multiple hypersensitive (immune mediated) reactions. Due to clinical phenotypes and to in vivo aspirin reactivity, adverse effects could be further classified. Aim: The aim of these studies was a comparison of hit ratios obtained by a humoral serum test measuring specific immunglobulin E (IgE) against a rapid cellular test measuring interleukin (IL)-6 release from sensitized mononuclear cells due to various suspect NSAID after symptoms within one year. Retrospective case studies were performed in in- and out-patients of our teaching hospital in Budapest, between 2003 and 2013. Method: Specific anti-NSAID IgE levels were determined by ELISA in 55 cases. The other matching group of patients consisted of 51 patients and 9 tolerant persons. Their separated cells’ supernatants were checked for IL-6 release incubated for 20 minutes by NSAID dilutions including intraassay controls by two-step ELISA assay. Both groups have been stratified according to “new” clinical classification. Results: Results have disclosed no significant differences among the distribution of clinical symptoms between the two groups. In both groups, 9 non-steroidal anti-inflammatory drugs were tested representing all frequently used compounds with COX-1 inhibitory potential. The overall positivity rate was nearly double (65.4% against 36.9%) within the group using IL-6 release assay against that with specific IgE as the diagnostic tool. In certain cases, non-drug components of commercial preparations prompted IL-6 release as well which was paralleled by in vivo test results. Positive in vitro tests were obtained in both groups with clinically cross-intolerant as well as single or multiple sensitized cases. Conclusion: The rates of single or multiple sensitized cases exceeded in both groups that of cross-intolerant patients. In some phenotypes belonging to the latter categories, IgE type antibodies against acetylsalicylic acid could be detected as well. IL-6 release assay was the more sensitive test. In addition to pure drugs, other ingredients of medicines could also be responsible for adverse events. Orv Hetil. 2018; 159(38): 1556–1566.

Polyphenols from Cymbopogon citratus inhibit iNOS expression and NO production – a promising source of new anti-inflammatory drugs

Planta Medica ◽  
2010 ◽  
Vol 76 (12) ◽  
Author(s):  
V Francisco ◽  
A Figueirinha ◽  
B Neves ◽  
C Garcia-Rodriguez ◽  
M Lopes ◽  
...  
Keyword(s):  
Inos Expression ◽  
No Production ◽  
Cymbopogon Citratus ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Promising Source

Heparin and proteoglycans as anti-inflammatory drugs

1996 ◽  
Vol 16 (01) ◽  
pp. 56-59
Author(s):  
D. J. Tyrrell ◽  
C. P. Page
Keyword(s):  
Inflammatory Diseases ◽  
Therapeutic Applications ◽  
Wide Range ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

SummaryEvidence continues to accumulate that the pleiotropic nature of heparin (beyond its anticoagulant potency) includes anti-inflammatory activities at a number of levels. It is clear that drugs exploiting these anti-inflammatory activities of heparin may offer exciting new therapeutic applications to the treatment of a wide range of inflammatory diseases.

Sign in / Sign up

Export Citation Format

Share Document